Unlearn Secures $50M Series C Funding to Revolutionize Clinical Trials with AI-Generated Digital Twins
Unlearn is at the forefront of using AI to enhance clinical trials.
Company Name: Unlearn
Location: San Francisco, CA
Sector: AI in Clinical Trials
Funding Details: Raised $50M in Series C funding led by Altimeter Capital, with participation from Radical Ventures, Wittington Ventures, Mubadala Capital, Epic Ventures, and Necessary Venture Capital.
Purpose of Investment: To advance AI in eliminating trial and error in medicine by investing in people, data, engineering capabilities, and long-term R&D initiatives.
Leadership: Charles Fisher, Ph.D., Founder and CEO
Product: Unlearn's AI models generate digital twins for each clinical trial participant, forecasting health outcomes under placebo conditions. This innovative approach enables TwinRCTs, highly powered clinical trials with smaller control groups, allowing more patients to receive experimental treatment and reducing the time to market for new drugs and therapies.
About Company: Unlearn is at the forefront of using AI to enhance clinical trials. By creating digital twins of participants, Unlearn aims to streamline the trial process, ensuring faster enrollment and quicker access to new treatments. The technology has been qualified by the European Medicines Agency and aligns with FDA guidance, marking a significant step forward in the integration of AI with clinical research.
